NASDAQ:RCKT - Rocket Pharmaceuticals Stock Price, Price Target & More

$17.27 +0.17 (+0.99 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$17.27
Today's Range$16.9001 - $17.39
52-Week Range$3.40 - $20.60
Volume202,037 shs
Average Volume357,337 shs
Market Capitalization$685.78 million
P/E RatioN/A
Dividend YieldN/A
Beta3.96

About Rocket Pharmaceuticals (NASDAQ:RCKT)

Rocket Pharmaceuticals logoRocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas. The company is headquartered in New York, New York.

Receive RCKT News and Ratings via Email

Sign-up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RCKT
CUSIPN/A
Phone646-440-9100

Debt

Debt-to-Equity Ratio1.04%
Current Ratio24.83%
Quick Ratio24.83%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.02 per share
Price / Book2.46

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-29,490,000.00
Net MarginsN/A
Return on Equity-53.72%
Return on Assets-27.09%

Miscellaneous

Employees20
Outstanding Shares39,440,000

How to Become a New Pot Stock Millionaire

Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals (NASDAQ:RCKT) posted its quarterly earnings data on Thursday, August, 3rd. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.47) by $0.23. View Rocket Pharmaceuticals' Earnings History.

When is Rocket Pharmaceuticals' next earnings date?

Rocket Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Rocket Pharmaceuticals.

What price target have analysts set for RCKT?

4 brokerages have issued 1 year target prices for Rocket Pharmaceuticals' shares. Their predictions range from $2.00 to $27.00. On average, they anticipate Rocket Pharmaceuticals' stock price to reach $10.6667 in the next year. View Analyst Ratings for Rocket Pharmaceuticals.

Are investors shorting Rocket Pharmaceuticals?

Rocket Pharmaceuticals saw a increase in short interest during the month of March. As of March 15th, there was short interest totalling 1,055,546 shares, an increase of 53.9% from the February 28th total of 685,907 shares. Based on an average daily volume of 361,033 shares, the short-interest ratio is currently 2.9 days. Approximately 2.9% of the shares of the stock are short sold.

Who are some of Rocket Pharmaceuticals' key competitors?

Who are Rocket Pharmaceuticals' key executives?

Rocket Pharmaceuticals' management team includes the folowing people:
  • Mr. Gaurav Shah M.D., Chief Exec. Officer
  • Mr. Brian Batchelder, Head of Fin. and VP
  • Ms. Kinnari Patel PharmD, MBA, Head of Regulatory, Pharmacovigilance & Compliance and VP
  • Mr. Jonathan Schwartz M.D., Chief Medical Officer and Head of Clinical Devel.
  • Mr. Naveen Yalamanchi, Chief Bus. Officer

Has Rocket Pharmaceuticals been receiving favorable news coverage?

Media coverage about RCKT stock has been trending somewhat positive on Friday, according to Accern. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Rocket Pharmaceuticals earned a media sentiment score of 0.05 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 45.43 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $17.27.

How big of a company is Rocket Pharmaceuticals?

Rocket Pharmaceuticals has a market capitalization of $685.78 million. Rocket Pharmaceuticals employs 20 workers across the globe.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 430 EAST 29TH STREET SUITE 1040, NEW YORK NY, 10016. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected]


MarketBeat Community Rating for Rocket Pharmaceuticals (RCKT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  248
MarketBeat's community ratings are surveys of what our community members think about Rocket Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCKT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCKT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Rocket Pharmaceuticals in the last 12 months. Their average twelve-month price target is $10.6667, suggesting that the stock has a possible downside of 38.24%. The high price target for RCKT is $27.00 and the low price target for RCKT is $2.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.502.502.002.25
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.6667$10.6667$2.50$4.50
Price Target Upside: 38.24% downside40.64% downside163.16% upside373.68% upside

Rocket Pharmaceuticals (NASDAQ:RCKT) Consensus Price Target History

Price Target History for Rocket Pharmaceuticals (NASDAQ:RCKT)

Rocket Pharmaceuticals (NASDAQ:RCKT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2018CowenInitiated CoverageOutperformMediumView Rating Details
1/30/2018Evercore ISIInitiated CoverageOutperform -> Outperform$27.00HighView Rating Details
7/12/2017Canaccord GenuityDowngradeBuy -> HoldMediumView Rating Details
7/11/2017HC WainwrightDowngradeBuy -> Neutral$2.00HighView Rating Details
1/3/2017Piper JaffrayDowngradeOverweight -> Neutral$3.00N/AView Rating Details
12/1/2016Roth CapitalInitiated CoverageBuy$10.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Rocket Pharmaceuticals (NASDAQ:RCKT) Earnings History and Estimates Chart

Earnings by Quarter for Rocket Pharmaceuticals (NASDAQ:RCKT)

Rocket Pharmaceuticals (NASDAQ RCKT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018        
8/3/2017Q2 2017($0.47)($0.24)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.3930)($0.40)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.4320)($0.4810)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.45)($0.41)ViewN/AView Earnings Details
8/10/2016Q2($0.40)($0.33)ViewN/AView Earnings Details
5/11/2016Q1($0.22)($0.38)ViewN/AView Earnings Details
3/23/2016Q4($0.37)($0.13)ViewN/AView Earnings Details
11/12/2015Q3 2015($1.84)($1.00)ViewN/AView Earnings Details
8/6/2015Q2 2015($0.29)($0.26)ViewN/AView Earnings Details
5/15/2015Q1 2015$0.80ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Rocket Pharmaceuticals (NASDAQ:RCKT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Rocket Pharmaceuticals (NASDAQ RCKT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.30%
Insider Trading History for Rocket Pharmaceuticals (NASDAQ:RCKT)

Rocket Pharmaceuticals (NASDAQ RCKT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/6/2017David P. SouthwellInsiderBuy60,000$1.75$105,000.00View SEC Filing  
5/13/2016J Martin CarrollDirectorBuy10,000$9.03$90,300.0010,000View SEC Filing  
2/23/2015Argeris N KarabelasDirectorBuy603,832$6.00$3,622,992.00View SEC Filing  
2/23/2015Park Bioventures Lp DevonMajor ShareholderBuy814,166$6.00$4,884,996.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Rocket Pharmaceuticals (NASDAQ RCKT) News Headlines

Source:
DateHeadline
Rocket Pharmaceuticals (RCKT) Given a $3.00 Price Target by Canaccord Genuity AnalystsRocket Pharmaceuticals (RCKT) Given a $3.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 20 at 2:25 PM
Rocket Pharmaceuticals (RCKT) Downgraded by Canaccord GenuityRocket Pharmaceuticals (RCKT) Downgraded by Canaccord Genuity
www.americanbankingnews.com - April 18 at 9:10 PM
Rocket Pharmaceuticals (RCKT) Receives Average Rating of "Buy" from AnalystsRocket Pharmaceuticals (RCKT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 15 at 8:07 AM
Rocket Pharmaceuticals (RCKT) Upgraded to "Hold" by ValuEngineRocket Pharmaceuticals (RCKT) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - April 3 at 10:40 AM
We Are Seeing a Dreary Liquidation in the Stock MarketWe Are Seeing a Dreary Liquidation in the Stock Market
finance.yahoo.com - April 2 at 4:36 PM
Rocket Pharmaceuticals Inc (RCKT) Short Interest UpdateRocket Pharmaceuticals Inc (RCKT) Short Interest Update
www.americanbankingnews.com - March 30 at 2:02 AM
Rocket Pharmaceuticals (RCKT) Earns Outperform Rating from Analysts at Evercore ISIRocket Pharmaceuticals (RCKT) Earns Outperform Rating from Analysts at Evercore ISI
www.americanbankingnews.com - March 26 at 3:42 PM
Comparing Global Blood Therapeutics (GBT) & Rocket Pharmaceuticals (RCKT)Comparing Global Blood Therapeutics (GBT) & Rocket Pharmaceuticals (RCKT)
www.americanbankingnews.com - March 25 at 9:23 AM
Rocket Pharmaceuticals Inc (RCKT) Receives Consensus Recommendation of "Hold" from BrokeragesRocket Pharmaceuticals Inc (RCKT) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 21 at 11:31 AM
Rocket Pharmaceuticals (RCKT) and Its Peers Head to Head ComparisonRocket Pharmaceuticals (RCKT) and Its Peers Head to Head Comparison
www.americanbankingnews.com - March 13 at 9:36 AM
Head to Head Contrast: Rocket Pharmaceuticals (RCKT) & Its PeersHead to Head Contrast: Rocket Pharmaceuticals (RCKT) & Its Peers
www.americanbankingnews.com - March 12 at 3:10 AM
Cowen Starts Rocket Pharmaceuticals (RCKT) at Outperform - StreetInsider.comCowen Starts Rocket Pharmaceuticals (RCKT) at Outperform - StreetInsider.com
www.streetinsider.com - March 10 at 5:28 PM
Rocket Pharmaceuticals (RCKT) Coverage Initiated at CowenRocket Pharmaceuticals (RCKT) Coverage Initiated at Cowen
www.americanbankingnews.com - March 9 at 4:23 PM
Rocket Pharmaceuticals to Present at the Cowen & Company 38 - Business Wire (press release)Rocket Pharmaceuticals to Present at the Cowen & Company 38 - Business Wire (press release)
www.businesswire.com - March 7 at 9:28 AM
Rocket Pharmaceuticals Reports Full Year 2017 Financial Results and Operational Highlights - Business Wire (press release)Rocket Pharmaceuticals Reports Full Year 2017 Financial Results and Operational Highlights - Business Wire (press release)
www.businesswire.com - March 7 at 9:28 AM
Rocket Pharmaceuticals Reports Full Year 2017 Financial Results and Operational HighlightsRocket Pharmaceuticals Reports Full Year 2017 Financial Results and Operational Highlights
finance.yahoo.com - March 6 at 9:12 AM
Rocket Pharmaceuticals to Present at the Cowen & Company 38th Annual Health Care ConferenceRocket Pharmaceuticals to Present at the Cowen & Company 38th Annual Health Care Conference
finance.yahoo.com - March 5 at 9:31 AM
Rocket Pharmaceuticals Inc (RCKT) Given Average Recommendation of "Hold" by BrokeragesRocket Pharmaceuticals Inc (RCKT) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 24 at 8:08 AM
Intec Pharma (NTEC) vs. Rocket Pharmaceuticals (RCKT) Head to Head ReviewIntec Pharma (NTEC) vs. Rocket Pharmaceuticals (RCKT) Head to Head Review
www.americanbankingnews.com - February 20 at 11:18 PM
Analyzing Rocket Pharmaceuticals (RCKT) and Its CompetitorsAnalyzing Rocket Pharmaceuticals (RCKT) and Its Competitors
www.americanbankingnews.com - February 18 at 12:08 PM
Analyzing Rocket Pharmaceuticals (RCKT) and Its RivalsAnalyzing Rocket Pharmaceuticals (RCKT) and Its Rivals
www.americanbankingnews.com - February 14 at 3:14 PM
Rocket Pharmaceuticals Announces Participation in a Fireside Chat at the Leerink Partners 7th Annual Global Healthcare ConferenceRocket Pharmaceuticals Announces Participation in a Fireside Chat at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 7 at 9:18 AM
Rocket Pharmaceuticals Inc (RCKT) Receives Average Recommendation of "Hold" from AnalystsRocket Pharmaceuticals Inc (RCKT) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 30 at 9:40 AM
 Rocket Pharmaceuticals Inc (RCKT) Receives Average Recommendation of "Hold" from Brokerages Rocket Pharmaceuticals Inc (RCKT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 27 at 7:12 PM
Rocket Pharmaceuticals Announces Proposed Public Offering of Common StockRocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 24 at 9:44 AM
Rocket Pharmaceuticals Prices Public Offering of Common StockRocket Pharmaceuticals Prices Public Offering of Common Stock
finance.yahoo.com - January 24 at 9:44 AM
Critical Comparison: Anthera Pharmaceuticals (ANTH) vs. Rocket Pharmaceuticals (RCKT)Critical Comparison: Anthera Pharmaceuticals (ANTH) vs. Rocket Pharmaceuticals (RCKT)
www.americanbankingnews.com - January 21 at 11:10 PM
BRIEF-Tang Capital Partners Reports 8.1 Pct Passive Stake In Rocket Pharmaceuticals - SEC FilingBRIEF-Tang Capital Partners Reports 8.1 Pct Passive Stake In Rocket Pharmaceuticals - SEC Filing
www.reuters.com - January 17 at 12:05 PM
Rocket Pharmaceuticals (RCKT) Upgraded to Sell by ValuEngineRocket Pharmaceuticals (RCKT) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - January 9 at 6:26 PM

SEC Filings

Rocket Pharmaceuticals (NASDAQ:RCKT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Rocket Pharmaceuticals (NASDAQ:RCKT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Rocket Pharmaceuticals (NASDAQ RCKT) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.